TXA and Corona Virus 2019 (COVID19) in Outpatients

• Status: Terminated
• Trial end date: 2021-04-21
• Target enrollment: 0
• Participant gender: All

Summary

A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Alabama at Birmingham
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Positive COVID-19 test

• Outpatient

• Age >/= 19 y.o.

Exclusion Criteria:

• Allergic reaction to tranexamic acid

• History of hypercoagulation disorders (deep venous thrombosis, pulmonary thromboembolism)

• Ongoing anticoagulation

• History of GI bleeding

• History of Seizures

• Cardiac or other vascular stents

• History of severe renal disease

• History of intracranial hemorrhage